Details for New Drug Application (NDA): 020707
✉ Email this page to a colleague
The generic ingredient in SKELID is tiludronate disodium. There is one drug master file entry for this compound. Additional details are available on the tiludronate disodium profile page.
Summary for 020707
Tradename: | SKELID |
Applicant: | Sanofi Aventis Us |
Ingredient: | tiludronate disodium |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Mar 7, 1997 | TE: | RLD: | Yes |
Expired US Patents for NDA 020707
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription